Acorda Therapeutics, Inc.
MarketLine (a Datamonitor Company)
08 Jan 2014
Available for Immediate Download
Acorda Therapeutics, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Acorda Therapeutics, Inc. required for business and competitor intelligence needs - A study of the major internal and external factors affecting Acorda Therapeutics, Inc. in the form of a SWOT analysis - An in-depth view of the business model of Acorda Therapeutics, Inc. including a breakdown and examination of key business segments - Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Acorda Therapeutics, Inc. - Intelligence on Acorda Therapeutics, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Acorda Therapeutics, Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Acorda Therapeutics (Acorda or 'the company') is a commercial-stage biotechnology company engaged in the development and marketing of therapies to help restore function in persons with spinal cord injury, multiple sclerosis and related conditions of the central nervous system. Acorda's marketed products include Ampyra/Fampyra (dalfampridine) and Zanaflex capsules and tablets (tizanidine hydrochloride). The company primarily operates in the US, where it is headquartered in Ardsley, New York, and employed 378 people as of February 13, 2013. The company recorded revenues of $305.8 million during the financial year ended December 2012 (FY2012), an increase of 4.6% over FY2011. The operating profit of the company was $25.6 million in FY2012, a decrease of 27% over FY2011. The net profit was $155 million in FY2012, as compared to a net profit of $30.6 million in FY2011. Reasons to Purchase: - Gain understanding of Acorda Therapeutics, Inc. and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Acorda Therapeutics, Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Acorda Therapeutics, Inc.’s business structure, strategy and prospects